Executive Director Resignation
Thursday 29th July 2010, Melbourne Australia: Halcygen Pharmaceuticals Limited today announced Executive Director and Chief Operating Officer Craig Bottomley would step down from the role after 5 years with the company due to family reasons.
Lisa Pendlebury would assume the role of Investor Relations Manager. Lisa was previously the Investor Relations Manager at Pacific Brands. She spent 7 years at Pacific Brands in various business development roles. Prior to Pacific Brands, Lisa worked at CVC Asia Pacific and JPMorgan.
Halcygen’s CEO Dr Roger Aston said, “The Board and I would like to thank Craig Bottomley for his significant contribution to the company. He has played a key role in establishing the Halcygen business and in the transformation of the company following the acquisition of Mayne Pharma International Pty Ltd in 2009.”
“The company has proven cash flows as recently reported and is well placed going forward to expand from this strong position”
“The Board is also in the process of recruiting another non-executive director with suitable experience to complement the backgrounds of the other directors and it is also looking to further strengthen the senior management team in the coming months.”
For further information contact:
HalcyGen: Dr Roger Aston 0402 762 204
Lisa Pendlebury 0419 548 434, firstname.lastname@example.org
HalcyGen was founded to bridge the gap between main stream pharmaceutical companies and high volume generics companies through the development and licensing of new improved proprietary generic formulations known as "Super Generics" or "High Functionality Generics".
HalcyGen acquired Mayne Pharma International Pty Ltd (MPI) in November 2009.
The company has substantial assets and revenues.
MPI was formerly known as FH Faulding & Co Ltd, and is a specialist pharmaceutical company with an intellectual property portfolio built around the optimisation and delivery of oral dosage form drugs. MPI has a long and successful history in developing and commercialising improved pharmaceuticals, and has launched and marketed numerous products through partnerships with global licensees.
MPI’s facilities are based in South Australia on a 32 acre site. The facility also undertakes the manufacture of products under contract for third parties to TGA, FDA and EU regulatory guidelines.